
Novartis AG
NVSHealthcare|Drug Manufacturers - General|CH
$162.55
+0.62 (+0.38%)
DCF Value
$269.57
Graham Number
$48.20
Cash / Share
$4.75
Next Earnings Report
Feb 3, 2027
EPS est. $2.23 · Revenue est. $14.69B
Financing Filings (last 12 months)
2
Shelf registrations / offering prospectuses — latest Mar 17, 2026 (424B5). Possible dilution.
Upcoming Data Readouts (44)
Dec 2026
Est. completion
Dec 2026
Est. completion
P2Metastatic Castration-Resistant Prostate Cancer (mCRPC)
Study of Lutetium (177Lu) Vipivotide Tetraxetan in mCRPC Participants With Moderately and Severely Impaired and With Normal Renal Function
NCT06004661n=23
Dec 2026
Est. completion
P1Elevated Blood Pressure
HJB647 Phase 1b Study in Japanese Healthy Participants With Elevated Blood Pressure and Patients With Hypertension
NCT07644364n=64
Dec 2026
Est. completion
Multiple Sclerosis
A Study Comparing Effectiveness of Kesimpta® (Ofatumumab) Versus Ocrevus® (Ocrelizumab) in Real-world Practice
NCT07779460n=7,466
Dec 2026
Est. completion
Feb 2027
Est. completion
P1P2Advanced Soft-tissue Sarcoma
HDM201 and Pazopanib in Patients With P53 Wild-type Advanced/Metastatic Soft Tissue Sarcomas
NCT05180695n=47
Feb 2027
Est. completion
P1P2Breast Cancer
Study of LEE011, BYL719 and Letrozole in Advanced ER+ Breast Cancer
NCT01872260n=259
Apr 2027
Est. completion
P4Coronary Heart Disease
Inclisiran Effectiveness in China: a Pragmatic Randomized Trial
NCT06941792n=1,590
May 2027
Est. completion
P4Atherosclerotic Cardiovascular Disease
Study to Evaluate the Impact of a Targeted Lipid Optimization Program on LDL-C Control in At-risk Adult Patients With Dyslipidemia
NCT07034690n=326
Jul 2027
Est. completion
P3Ovarian Neoplasm Epithelial
MAintenance Therapy With Aromatase Inhibitor in Epithelial Ovarian Cancer (MATAO)
NCT04111978n=540
Aug 2027
Est. completion
Hypertension
A Real-world Study of the Effectiveness of Angiotensin Receptor-Neprilysin Inhibitor Therapy in Hypertensive Patients in the United Arab Emirates
NCT07465666n=500
Sep 2027
Est. completion
Dec 2027
Est. completion
Advanced Breast Cancer
Southeast Netherlands Advanced Metastatic Breast Cancer Registry
NCT03577197n=7,000
Feb 2028
Est. completion
Melanoma
Effectiveness and Safety of Dabrafenib in Combination With Trametinib as Adjuvant Treatment for Chinese Patients With Stage III BRAF V600 Mutation-positive Melanoma After Complete Resection
NCT04666272n=78
Apr 2028
Est. completion
Jun 2028
Est. completion
P2Non-segmental Vitiligo
A Phase IIb Dose-ranging Study to Assess the Efficacy and Safety of GIA632 in Participants With Non-segmental Vitiligo
NCT07431177n=210
Jun 2028
Est. completion
P1Advanced Malignancies and Hepatic Impairment
Pharmacokinetics and Safety Study of Pelabresib in Patients With Advanced Malignancies and Hepatic Impairment
NCT07422610n=24
Jul 2028
Est. completion
P1P2PSMA-positive Metastatic Castration Resistant Prostate Cancer (mCRPC) With Prior Exposure to One Prior ARPI Who Are Candidates for Taxane-based Chemotherapy
A Phase Ib/II Open-label Study of AMO959 With Lutetium (177Lu) Vipivotide Tetraxetan (AAA617) in Combination With ARPI in Adult Participants With PSMA-positive mCRPC
NCT07226986n=123
Aug 2028
Est. completion
P1Large-cell Lymphoma
CAR-T ceLL for Eradication of Active Residual Disease in LBCL (CLEAR-1 Study)
NCT07443137n=20
Sep 2028
Est. completion
Hidradenitis Suppurativa
Long Term Observational Study to Collect in a Real-world populatIon Data on the Treatment Pattern of Secukinumab in Adult Patients With Moderate to Severe HS Within the Italian Population
NCT07543419n=250
Awaiting Results (12)
Trials past primary completion date but still active — data readout may be imminent.
Oct 2026
P1
NEPC Study: An Exploratory Safety and Efficacy Study With PSMA, SSTR2 and GRPR Targeted Radioligand Therapy in Metastatic Neuroendocrine Prostate Cancer.
NCT06379217Jul 2026
P1
Study of Safety, Tolerability, Pharmacodynamics and Pharmacokinetics of NIO752 in Early Alzheimer's Disease Participants
NCT05469360Jul 2026
P1
Study of Pelabresib add-on to Ruxolitinib in Japanese Adult Patients With Myelofibrosis
NCT07340138Nov 2024
P2
Study of Efficacy and Safety of JDQ443 Single-agent as First-line Treatment for Patients With Locally Advanced or Metastatic KRAS G12C- Mutated Non-small Cell Lung Cancer With a PD-L1 Expression < 1% or a PD-L1 Expression ≥ 1% and an STK11 Co-mutation.
NCT05445843Jan 2024
P2
Trametinib in Treating Patients With Progressive Metastatic Hormone-Resistant Prostate Cancer
NCT02881242Jul 2023
Real World Study Using Comprehensive Genomic Data on the Next Treatment Decision Making in Metastatic Breast Cancer
NCT04497285Recent Press Releases
BioArctic collaborator Novartis terminates agreement
Nov 2, 2026 · PRNewsWire
INVESTOR ALERT: Pomerantz Law Firm Investigates Claims On Behalf of Investors of Novartis AG - NVS
Oct 15, 2026 · PRNewsWire
INVESTOR ALERT: Pomerantz Law Firm Investigates Claims On Behalf of Investors of Novartis AG - NVS
Oct 13, 2026 · GlobeNewsWire
INVESTOR ALERT: Pomerantz Law Firm Investigates Claims On Behalf of Investors of Novartis AG - NVS
Oct 8, 2026 · PRNewsWire
INVESTOR ALERT: Pomerantz Law Firm Investigates Claims On Behalf of Investors of Novartis AG - NVS
Oct 6, 2026 · GlobeNewsWire
INVESTOR ALERT: Pomerantz Law Firm Investigates Claims On Behalf of Investors of Novartis AG - NVS
Oct 1, 2026 · PRNewsWire
INVESTOR ALERT: Pomerantz Law Firm Investigates Claims On Behalf of Investors of Novartis AG - NVS
Sep 29, 2026 · GlobeNewsWire
Novartis Investigation Notice: SueWallSt Notifies Investors of Pending Investigation Into Novartis (NVS)
Sep 9, 2026 · PRNewsWire
Royalty Pharma announces update on Novartis' Phase 3 topline results for pelacarsen
Sep 4, 2026 · GlobeNewsWire
SEC Filings (61)
Last two years from EDGAR. Insider Form 4s are on the Ownership tab.
| Filed | Form | What it is | Links |
|---|---|---|---|
| Oct 27, 2026 | SC 13G/A | Passive 5%+ stake | DocumentIndex |
| Oct 27, 2026 | 6-K | Foreign issuer report | DocumentIndex |
| Sep 8, 2026 | 6-K | Foreign issuer report | DocumentIndex |
| Sep 4, 2026 | 6-K | Foreign issuer report | DocumentIndex |
| Sep 1, 2026 | 6-K | Foreign issuer report | DocumentIndex |
| Jul 21, 2026 | 6-K | Foreign issuer report | DocumentIndex |
| Jun 11, 2026 | 6-K | Foreign issuer report | DocumentIndex |
| Apr 28, 2026 | 6-K | Foreign issuer report | DocumentIndex |
| Mar 18, 2026 | 6-K | Foreign issuer report | DocumentIndex |
| Mar 17, 2026 | 424B5 | Offering prospectus | DocumentIndex |
| Mar 17, 2026 | FWP | DocumentIndex | |
| Mar 16, 2026 | 424B5 | Offering prospectus | DocumentIndex |
| Feb 4, 2026 | S-8 | Employee stock plan | DocumentIndex |
| Feb 4, 2026 | 6-K | Foreign issuer report | DocumentIndex |
| Feb 4, 2026 | 6-K | Foreign issuer report | DocumentIndex |
| Feb 4, 2026 | IRANNOTICE | DocumentIndex | |
| Feb 4, 2026 | 20-F | Annual report (foreign) | DocumentIndex |
| Jan 16, 2026 | S-8 POS | Employee stock plan | DocumentIndex |
| Jan 16, 2026 | S-8 POS | Employee stock plan | DocumentIndex |
| Jan 16, 2026 | S-8 POS | Employee stock plan | DocumentIndex |
| Jan 16, 2026 | S-8 POS | Employee stock plan | DocumentIndex |
| Jan 14, 2026 | DFAN14A | DocumentIndex | |
| Jan 12, 2026 | DFAN14A | DocumentIndex | |
| Nov 25, 2025 | 6-K | Foreign issuer report | DocumentIndex |
| Nov 20, 2025 | 6-K | Foreign issuer report | DocumentIndex |
| Nov 5, 2025 | 6-K | Foreign issuer report | DocumentIndex |
| Nov 4, 2025 | 424B5 | Offering prospectus | DocumentIndex |
| Nov 4, 2025 | FWP | DocumentIndex | |
| Nov 3, 2025 | 424B5 | Offering prospectus | DocumentIndex |
| Oct 28, 2025 | DFAN14A | DocumentIndex | |
| Oct 28, 2025 | SC TO-T/A | Tender offer | DocumentIndex |
| Oct 28, 2025 | DFAN14A | DocumentIndex | |
| Oct 28, 2025 | 6-K | Foreign issuer report | DocumentIndex |
| Oct 27, 2025 | DFAN14A | DocumentIndex | |
| Oct 27, 2025 | DFAN14A | DocumentIndex | |
| Oct 27, 2025 | DFAN14A | DocumentIndex | |
| Oct 27, 2025 | 6-K | Foreign issuer report | DocumentIndex |
| Oct 22, 2025 | SC TO-T/A | Tender offer | DocumentIndex |
| Sep 30, 2025 | 6-K | Foreign issuer report | DocumentIndex |
| Sep 29, 2025 | SC TO-T | Tender offer | DocumentIndex |